相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
66.7%
Enrolling By Invitation
1
16.7%
招募中
1
16.7%
暂无批准数据
- NeuraLight's ASH biomarker, measuring saccadic hypometria via eye movements, detected significant Parkinson's progression across two independent cohorts (P < 0.0001). - The gold-standard MDS-UPDRS III clinical scale, scored by clinicians at the same sites over the same period, failed to reach statistical significance. - The study was co-authored by Prof. Goetz and Prof. Rascol, two developers of the MDS-UPDRS scale itself, lending exceptional credibility to the findings. - Objective, reproducible biomarkers like ASH could enable more efficient clinical trials and increase confidence in detecting treatment effects for disease-modifying therapies.
- NeuraLight completed PALOMA, a 12-month multicenter study with 300 Parkinson's patients, representing one of the largest longitudinal trials using eye-movement biomarkers to track disease progression. - The study demonstrated that NeuraLight's eye-movement biomarkers correlate significantly with standard clinical assessments like MDS-UPDRS and MoCA, with 10x more sensitivity than current gold standards. - The platform's 10-minute tablet-based assessment offers a more objective and scalable approach to monitoring Parkinson's progression compared to traditional clinical tools. - Results suggest this technology could transform neurological drug development by providing more sensitive and repeatable measurements for clinical trials.
- The precision medicine landscape is rapidly evolving, with gene therapies expected to generate nearly $54 billion in sales by 2029, while cell therapies are projected to reach $52 billion in the same period. - Artificial Intelligence is revolutionizing precision medicine by improving clinical trial recruitment, enhancing CRISPR technology precision, and enabling better biomarker identification for targeted treatments. - Industry experts emphasize the critical role of standardized biomarker testing and data collection in advancing precision medicine, with applications expanding beyond oncology into autoimmune and neurological diseases.
